The Avicenna Alliance itself has its origins in the Avicenna Roadmap, a 2-year EU funded project, led by DG Connect whose goal was to create a research and technological development Roadmap outlining a strategy for in silico Clinical Trials (ISCT).

 Built into the European Commission’s project requirements was a plan to establish a pre-competitive Association – the Avicenna Alliance, that would represent the needs of the in silico medicine community and provide the Commission and other policy makers with expert advice in this field.

The Avicenna Alliance operating since 2016, now works with members to implement this Roadmap and identify policy and regulatory obstacles to the enhancement of in silico medicine.

The Avicenna Alliance is a researcher and industry partnership with 50% membership of the Virtual Physiological Human Initiative (VPH) and 50% representation of the medical devices, pharmaceuticals, software and cosmetics industries.

By engaging both researchers and industry in the conversation on how to roll out this roadmap, the Avicenna Alliance is the one stop shop for all things in silico medicine at EU level.

To find out if you could benefit from Membership of the Avicenna Alliance, click here.

The completed Avicenna Roadmap

Downloadable version (5,6 MB)

More information about the Avicenna Roadmap can be found here

Avicenna Alliance news

In silico method mentioned in JRC report on alternatives to animal testing

On 7 February, the European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) - which is an...

find out more ›

Artificial Intelligence and clinical research: which issues remain?

This issue is discussed in the new article written under the direction of Vincent Diebolt, Director of the French Clinical Research...

find out more ›

FEops  joins Avicenna Alliance

As further evidence of the Alliance’s growing momentum, Avicenna Alliance is happy to announce the newest addition to our list of members: FEops.

find out more ›

Show all activites